AG-1478

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H14ClN3O2
Molecular Weight	315.754
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=NC=NC(NC3=CC=CC(Cl)=C3)=C2C=C1OC

InChI

InChIKey=GFNNBHLJANVSQV-UHFFFAOYSA-N

InChI=1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)

HIDE SMILES / InChI

Molecular Formula	C16H14ClN3O2
Molecular Weight	315.754
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11410322 | https://www.ncbi.nlm.nih.gov/pubmed/15205403| https://www.ncbi.nlm.nih.gov/pubmed/7892601

AG1478 (also known as Tyrphostin AG 1478 ) is a selective EGFR inhibitor, which induced cell cycle arrest in G1 phase, is developed as potential drug for nasopharyngeal carcinoma treatment. In addition was shown, that AG1478 effectively blocked the leiomyoma cell growth and is unaffected by the presence of physiological concentrations of progesterone and estradiol. The growth-arresting properties of AG1478, unaffected by ovarian steroidal hormones, identify it as a potential lead agent for the non-surgical management of uterine leiomyomas. Also was investigated the action of the combination AG1478 in combination with HGF tyrosine kinase inhibitors on non-small cell lung cancer (NSCLC) cells, and was suggested, that these combinations of drugs could be potentially used for treatment of NSCLC.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Epidermal growth factor receptor erbB1 58 Target ID: CHEMBL203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15205403	Inhibitor 8297		3.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Nasopharyngeal carcinoma 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11410322	Primary	Basic research	Unknown Approved Use Unknown
Uterine leiomyomata 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15205403	Primary	Basic research	Unknown Approved Use Unknown
Non-small cell lung cancer 206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19240370	Primary	Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.	1996 Sep 1	8752145
UV-Vis spectroscopy and solvatochromism of the tyrosine kinase inhibitor AG-1478.	2016 Jul 5	27092736

Patents

Sample Use Guides

In Vivo Use Guide

xenografted mice: treated with saline as placebo, 0.4 mg AG1478 i.p.

Route of Administration: Intravenous

In Vitro Use Guide

AG1478 (1-1000 nM) significantly inhibited both LPS-induced and TNF-α-induced secretion of MUC5AC and IL-8 from cultured NCI-H292 cells in a dose-dependent manner. The expression of MUC5AC and IL-8 messenger RNAs was also significantly inhibited. Intranasal instillation of AG1478 one hour after intranasal LPS instillation significantly inhibited LPS-induced goblet cell metaplasia, mucus production, and neutrophil infiltration in rat nasal epithelium, as did intraperitoneal injection of AG1478 one hour before LPS instillation.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:37:48 GMT 2023` Edited by `admin` on `Fri Dec 15 19:37:48 GMT 2023`
Record UNII	SUH0SEZ9HY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AG-1478

Code

English

AG-1478 FREE BASE

Code

English

NSC-693255

Code

English

4-QUINAZOLINAMINE, N-(3-CHLOROPHENYL)-6,7-DIMETHOXY-

Systematic Name

English

TYRPHOSTIN AG-1478

Common Name

English

TYRPHOSTIN AG 1478

Common Name

English

(3-CHLOROPHENYL)(6,7-DIMETHOXYQUINAZOLIN-4-YL)AMINE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1757